Ebola drug maker’s stock rises
There is no cure for Ebola. But don’t tell that to traders. Shares of a US-based company working on a drug to treat the infectious disease surged nearly 40% last week. Tekmira Pharmaceuticals popped on much higher trading volume than usual because investors are hopeful that health agencies in the United States might approve its drug, known as TKM-Ebola. But investors buying this stock now need to be extremely careful. CNN reported Monday that two Americans who were infected with the Ebola virus in Liberia were treated with a drug made by privately-held San Diego company Mapp Biopharmaceutical. Shares of Tekmira, which were up as much as 26% at one point Monday, gave up all of their gains following the CNN report and finished the day down 7%. Meanwhile, shares of BioCryst Pharmaceuticals (BCRX), another small biotech working on a drug that could be used to treat Ebola, were up more than 5% Monday. Jason Kolbert, an analyst with Maxim Group who covers Tekmira, said in an interview t...